Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 1, 2013, Pages 10-11

  Chang, Kwok Chiu ^a   Dheda, Keertan ^b,c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; THIOAMIDE;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; BRAZIL; CHINA; DRUG MEGADOSE; DYSGLYCEMIA; EDITORIAL; HUMAN; INDIA; INFECTION SENSITIVITY; LIVER TOXICITY; MULTIDRUG RESISTANT TUBERCULOSIS; POVERTY; PREMATURITY; PRIORITY JOURNAL; QT PROLONGATION; SOUTH AFRICA; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; FEMALE; OFLOXACIN; PYRAZINAMIDE; QUINOLINES; TUBERCULOSIS;

EID: 84880180528     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201304-0697ED     Document Type: Editorial

References (26)

1. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: World Health Organization; 2012.
2. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE 2013;8:e54587.
3. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-528.
4. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Codecasa LR, Spanevello A, Cirillo DM; SMIRA/TBNET Study Group. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008;31:904-905.
5. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-1481. (Pubitemid 37290060)
6. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
7. Conde MB, Efron A, Loredo C, De Souza GRM, Grça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009;373:1183-1189.
8. Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, FitzGerald JM. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005;128:1406-1413. (Pubitemid 41324425)
9. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
10. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;29:374-379. (Pubitemid 46349590)
11. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612. (Pubitemid 43845020)
12. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolonecontaining third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122. (Pubitemid 37229566)
13. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 2013;188:97-102.
14. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MCS, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119-128. (Pubitemid 36056718)
15. Chang K-C, Leung C-C, YewW-W, Leung EC-C, Leung W-M, Tam C-M, Zhang Y. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012; 56:5465-5475.
16. ShiW, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE III, Wang H, Zhang W, Zhang Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011;333:1630-1632.
17. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991;143:700-706.
18. Aung KJM, Declercq E, Ali MA, Naha S, Datta Roy SC, Taleb MA, Hossain MA, Rigouts L, Gumusboga A, Van Deun A. Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. Int J Tuberc Lung Dis 2012;16:455-461.
19. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008;177:1391-1396. (Pubitemid 351860918)
20. Keshavjee S, Gelmanova IY, Shin SS, Mishustin SP, Andreev YG, Atwood S, Furin JJ, Miller A. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis 2012;16:596-603.
21. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012;56:2223-2230.
22. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al.; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
23. Zhang Y, Chang K-C, Leung C-C, Yew W-W, Gicquel B, Fallows D, Kaplan G, Chaisson RE, Zhang W. "ZS-MDR-TB" versus "ZR-MDRTB": improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect 2012;1:e5.
24. Pierre-Audigier C, Surcouf C, Cadet-Daniel V, Namouchi A, Heng S, Murray A, Guillard B, Gicquel B. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012;16:221-223, i-ii.
25. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John M-A, Reubenson G, Govindasamy D, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-1807.
26. Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet 2012;379:773-775.